[{"orgOrder":0,"company":"R-Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Olokizumab","moa":"Il-6","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"R-Pharm \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"R-Pharm \/ Not Applicable"},{"orgOrder":0,"company":"R-Pharm","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"R-Pharm \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"R-Pharm \/ AstraZeneca"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Vector Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.A.E","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Ixabepilone","moa":"Tubulin","graph1":"Oncology","graph2":"Approved","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"R-Pharm \/ R-PHARM","highestDevelopmentStatusID":"12","companyTruncated":"R-Pharm \/ R-PHARM"}]

Find Clinical Drug Pipeline Developments & Deals by R-Pharm

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the agreement, R-PHARM US has appointed Vector Pharma as exclusive distributor to import, use, market, sell and distribute Ixempra (ixabepilone) in the Middle East & North African territories.

                          Brand Name : Ixempra

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 22, 2021

                          Lead Product(s) : Ixabepilone,Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Recipient : Vector Pharma

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The research aimed to evaluate the immunogenicity and safety of the Sputnik V and AZD1222 combined use. The research program will take place in several countries, enrolling 100 adults aged 18 years and older.

                          Brand Name : AZD1222

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          February 09, 2021

                          Lead Product(s) : ChAdOx1 nCoV-19,rAd26-S

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : AstraZeneca

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : R-Pharm JSC and Cromos Pharma has randomized the first patients into a clinical trial evaluating Olokizumab and RPH-104 in patients with severe COVID-19 infection.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          April 28, 2020

                          Lead Product(s) : Olokizumab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank